Washington University

The University of Texas System

Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

The Cleveland Clinic Foundation

Oregon Health & Science University

Southern Research Institute

Cleveland Clinic Lerner Research Institute

Michael S Diamond

Daved Henry Fremont

Christopher Nelson

Theodore Oliphant

Christopher Michael Doane

Corinne E Augelli-Szafran

Pei-Yong Shi

Ashish Kumar Pathak

Daniel Streblow

Sebastian Ulbert

Larissa Thackray

Omar Moukha-Chafiq

Nicole Haese

Alec Jay Hirsch

Jessica Lee Smith

Larry D Bratton

Arthur Kim

Katherine Basore

Milan Chheda

Matthew Gorman

Rong Zhang

Derek Platt

Jeremy Rich

Zhe Zhu

Baoling Ying

Shuklendu D Karyakarte

Pei Yong Shi

Estefania Fernandez

Haiyan Zhao

Grant Nybakken

Stefan Chabierski

Among the various aspects of the present disclosure is the provision of compositions and methods of treating arthritogenic alphavirus infection and methods of screening.

Compositions and methods for inhibition of alphavirus infection

The present disclosure involves a composition and method of treatment of glioblastoma, using ZIKA virus.

Zika virus strains for treatment of glioma

The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

6-aza-nucleoside prodrugs as antiviral agents for treating virus infections

The present disclosure relates to antibodies specific to Zika virus and methods for detecting Zika virus infection in a subject. The present disclosure also relates to therapeutic antibodies useful in reducing viral load.

Antibodies to zika virus and methods of use thereof

The present invention relates to mutant peptides of the E protein of the West Nile virus and other flaviviruses useful for discriminating flaviviral infections, as well as kits, methods and uses related thereto.

Distinguishing flavivirus infection using a recombinant mutant envelope protein

The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.

Antibodies against West Nile Virus and therapeutic and prophylactic uses thereof

The present invention provides crystalline forms of domain III of the West Nile Virus ('WNV') envelope protein in complex with a Fab fragment of a neutralizing antibody, methods of obtaining such crystals and high-resolution structures and atomic structure coordinates. The crystals of the invention and the atomic structural information are useful for solving crystal and solution structures of related and unrelated proteins, and for screening for, identifying or designing compounds or antibodies that bind to, modulate a biological activity of, or neutralize infection mediated by flaviviral envelope proteins.

Crystals and structure of domain III of West Nile Virus envelope protein in association with a Fab fragment of a neutralizing antibody

Growing community of inventors

St. Louis, MO, United States of America

Michael S Diamond